N1BI34 Stock Overview
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Neurocrine Biosciences, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$36.00 |
| 52 Week High | US$36.84 |
| 52 Week Low | US$22.83 |
| Beta | 0.28 |
| 1 Month Change | 1.18% |
| 3 Month Change | 1.24% |
| 1 Year Change | 40.41% |
| 3 Year Change | 44.00% |
| 5 Year Change | n/a |
| Change since IPO | 26.32% |
Recent News & Updates
Recent updates
Shareholder Returns
| N1BI34 | BR Biotechs | BR Market | |
|---|---|---|---|
| 7D | 0.9% | 1.0% | 0.5% |
| 1Y | 40.4% | -4.0% | 16.7% |
Return vs Industry: N1BI34 exceeded the BR Biotechs industry which returned -4.8% over the past year.
Return vs Market: N1BI34 exceeded the BR Market which returned 16.7% over the past year.
Price Volatility
| N1BI34 volatility | |
|---|---|
| N1BI34 Average Weekly Movement | 5.3% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 4.7% |
| 10% most volatile stocks in BR Market | 8.6% |
| 10% least volatile stocks in BR Market | 2.3% |
Stable Share Price: N1BI34 has not had significant price volatility in the past 3 months.
Volatility Over Time: N1BI34's weekly volatility (5%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1992 | 1,400 | Kevin Gorman | www.neurocrine.com |
Neurocrine Biosciences, Inc. discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids. Its product candidates in clinical development include valbenazine to treat dyskinetic cerebral palsy in pediatrics and adults; NBI-921352 to treat developmental and epileptic encephalopathy syndrome in pediatrics and adults; NBI-827104 to treat epileptic encephalopathy with continuous spike-and-wave during sleep; NBI-1076986 to treat movement disorders; crinecerfront to treat congenital adrenal hyperplasia in adults and children; EFMODY to treat congenital adrenal hyperplasia and adrenal insufficiency in adults; valbenazine for the adjunctive treatment of schizophrenia; NBI-1065845 for the treatment of inadequate response to treatment in major depressive disorder; luvadaxistat to treat cognitive impairment related to schizophrenia; NBI-1117568 for the treatment of schizophrenia; NBI-1070770 to treat major depressive disorder; NBI-1117570 for the treatment of symptoms of psychosis and cognition in neurological and neuropsychiatric conditions; and NBI-1117569, NBI-1117567, and NBI-1065890 to treat CNS indications.
Neurocrine Biosciences, Inc. Fundamentals Summary
| N1BI34 fundamental statistics | |
|---|---|
| Market cap | R$71.80b |
| Earnings (TTM) | R$1.92b |
| Revenue (TTM) | R$10.29b |
38.9x
P/E Ratio7.3x
P/S RatioIs N1BI34 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| N1BI34 income statement (TTM) | |
|---|---|
| Revenue | US$1.98b |
| Cost of Revenue | US$603.70m |
| Gross Profit | US$1.38b |
| Other Expenses | US$1.01b |
| Earnings | US$369.70m |
Last Reported Earnings
Mar 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.68 |
| Gross Margin | 69.54% |
| Net Profit Margin | 18.65% |
| Debt/Equity Ratio | 5.1% |
How did N1BI34 perform over the long term?
See historical performance and comparison